Chronic lymphocytic leukaemia: from genetics to treatment
F Bosch, R Dalla-Favera - Nature reviews Clinical oncology, 2019 - nature.com
Chronic lymphocytic leukaemia (CLL), the most frequent type of leukaemia in adults, is a
lymphoproliferative disorder that is characterized by the expansion of monoclonal, mature …
lymphoproliferative disorder that is characterized by the expansion of monoclonal, mature …
The molecular pathogenesis of chronic lymphocytic leukaemia
G Fabbri, R Dalla-Favera - Nature Reviews Cancer, 2016 - nature.com
Recent investigations have provided an increasingly complete picture of the genetic
landscape of chronic lymphocytic leukaemia (CLL). These analyses revealed that the CLL …
landscape of chronic lymphocytic leukaemia (CLL). These analyses revealed that the CLL …
Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia
PA Thompson, CS Tam, SM O'Brien… - Blood, The Journal …, 2016 - ashpublications.org
Accurate identification of patients likely to achieve long-progression-free survival (PFS) after
chemoimmunotherapy is essential given the availability of less toxic alternatives, such as …
chemoimmunotherapy is essential given the availability of less toxic alternatives, such as …
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial
S Stilgenbauer, A Schnaiter, P Paschka… - Blood, The Journal …, 2014 - ashpublications.org
Abstract Mutations in TP53, NOTCH1, and SF3B1 were analyzed in the CLL8 study
evaluating first-line therapy with fludarabine and cyclophosphamide (FC) or FC with …
evaluating first-line therapy with fludarabine and cyclophosphamide (FC) or FC with …
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL
In the phase 3 RESONATE study, ibrutinib demonstrated superior progression-free survival
(PFS), overall survival (OS) and overall response rate (ORR) compared with ofatumumab in …
(PFS), overall survival (OS) and overall response rate (ORR) compared with ofatumumab in …
Molecular profiling in diffuse large B‐cell lymphoma: why so many types of subtypes?
The term diffuse large B‐cell lymphoma (DLBCL) includes a heterogeneous collection of
biologically distinct tumours. This heterogeneity currently presents a barrier to the successful …
biologically distinct tumours. This heterogeneity currently presents a barrier to the successful …
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia
The identification of new genetic lesions in chronic lymphocytic leukemia (CLL) prompts a
comprehensive and dynamic prognostic algorithm including gene mutations and …
comprehensive and dynamic prognostic algorithm including gene mutations and …
From fly wings to targeted cancer therapies: a centennial for notch signaling
Since Notch phenotypes in Drosophila melanogaster were first identified 100 years ago,
Notch signaling has been extensively characterized as a regulator of cell-fate decisions in a …
Notch signaling has been extensively characterized as a regulator of cell-fate decisions in a …
[HTML][HTML] Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment
E Ten Hacken, JA Burger - Biochimica et Biophysica Acta (BBA)-Molecular …, 2016 - Elsevier
Abstract Chronic Lymphocytic Leukemia (CLL) is a malignancy of mature B lymphocytes
which are highly dependent on interactions with the tissue microenvironment for their …
which are highly dependent on interactions with the tissue microenvironment for their …
Biology and treatment of Richter syndrome
Richter syndrome (RS) is the development of an aggressive lymphoma in patients with
chronic lymphocytic leukemia (CLL). Two pathologic variants of RS are recognized: namely …
chronic lymphocytic leukemia (CLL). Two pathologic variants of RS are recognized: namely …